Shares of Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) were down 4.9% during mid-day trading on Wednesday . The company traded as low as $4.44 and last traded at $4.70. Approximately 8,527 shares changed hands during mid-day trading, a decline of 16% from the average daily volume of 10,173 shares. The stock had previously closed at $4.94.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Genenta Science in a research report on Wednesday, October 2nd.
Read Our Latest Stock Report on Genenta Science
Genenta Science Stock Performance
The firm has a 50 day simple moving average of $4.82 and a 200 day simple moving average of $4.09.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. bought a new stake in shares of Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 200,288 shares of the company's stock, valued at approximately $621,000. AlTi Global Inc. owned about 1.10% of Genenta Science at the end of the most recent quarter. Institutional investors and hedge funds own 15.13% of the company's stock.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Recommended Stories
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
